Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19403773 | 1.00 | MC4R (0.50) | MC4RL3MBTL1ALDH1A1TSHRCACNA1A | |
| SCHEMBL19403746 | 0.88 | L3MBTL1 (0.48) | MC4RL3MBTL1CACNA1ACACNA2D1CACNA1B | |
| SCHEMBL26330641 | 0.88 | L3MBTL1 (0.48) | MC4RL3MBTL1TSHRCACNA1ACACNA2D1 | |
| SCHEMBL26330833 | 0.88 | L3MBTL1 (0.48) | MC4RL3MBTL1CACNA1ACACNA2D1CACNA1B | |
| SCHEMBL23549955 | 0.84 | USP2 (0.55) | MC4RL3MBTL1ALDH1A1 | |
| SCHEMBL19403828 | 0.84 | USP2 (0.55) | MC4RL3MBTL1ALDH1A1 | |
| SCHEMBL20673507 | 0.84 | MC4R (0.49) | MC4RL3MBTL1 | |
| SCHEMBL19403753 | 0.83 | MC4R (0.45) | MC4RL3MBTL1TSHR | |
| SCHEMBL20673523 | 0.81 | MC4R (0.43) | MC4RL3MBTL1TSHR | |
| SCHEMBL3718118 | 0.77 | ADRA1B (0.48) | MC4RALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MC4R 3428/4885L3MBTL1 3218/4885ALDH1A1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.